Publications
Blue with acknowledgement to EurocanPlatform
WP1
 2012
 Thematic issue: Personalized cancer medicine – Guest editors: John Mendelsohn, Ulrik
Ringborg and Richard Schilsky. Mol Oncol (2012) April 6(2)
 2013
 Strategies to overcome clinical, regulatory, and financial challenges in the implementation
of personalized medicine. Tsimberidou AM, Ringborg U, Schilsky RL. Am Soc Clin Oncol Educ
Book. 2013;2013:118-25. doi: E10.1200/EdBook_AM.2013.33.118.
WP2
 2012
 The exposome: from concept to utility. Wild CP. Int J Epidemiol. (2012) Feb;41(1):24-32.
doi: 10.1093/ije/dyr236. Epub 2012 Jan 31.
 2013
 Measuring the exposome: A powerful basis for evaluating environmental exposures and
cancer risk. Wild CP, Scalbert A, Herceg Z. Environ Mol Mutagen. 2013 May 16. doi:
10.1002/em.21777. [Epub ahead of print]
 Meeting the global demands of epidemiologic transition - the indispensable role of cancer
prevention. Franceschi S, Wild CP. (2013) Mol Oncol. Feb;7(1):1-13. doi:
10.1016/j.molonc.2012.10.010. Epub 2012 Nov 17.
WP5
 2011
 Functional Viability Profiles of Breast Cancer. Brough R, Frankum JR, Sims D, Mackay A,
Mendes-Pereira AM, Bajrami I, Costa-Cabral S, Rafiq R, Ahmad AS, Cerone MA, Natrajan R,
Sharpe R, Shiu KK, Wetterskog D, Dedes KJ, Lambros MB, Rawjee T, Linardopoulos S, Reis-Filho
JS, Turner NC, Lord CJ, Ashworth A. (2011) Cancer Discov. Aug;1(3):260-73
doi:10.1158/2159-8290.CD-11-0107. Epub 2011 Aug 2
WP7
 2011
 Rapid validation of cancer genes in chimeras derived from established genetically
engineered mouse models. Huijbers, I.J., Krimpenfort, P., Berns, A., and Jonkers, J. (2011).
Bioassays 33, 701-710.
 BRCA1 RING function is essential for tumor suppression but dispensable for therapy
resistance. Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, Klijn C, van der
Heijden I, van der Gulden H, Wientjens E, Pieterse M, Catteau A, Green P, Solomon E, Morris JR,
Jonkers J. Cancer Cell. 2011 Dec 13;20(6):797-809.
 Studying therapy response and resistance in mouse models for BRCA1-deficient breast
cancer. Michalak EM, Jonkers J. J Mammary Gland Biol Neoplasia. 2011 Apr;16(1):41-50.
 Cell of Origin of Small Cell Lung Cancer: Inactivation of Trp53 and Rb1 in Distinct Cell
Types of Adult Mouse Lung. Sutherland K D, Proost N, Brouns I, Adriaensen D, Song J-Y, and
Berns A. (2011). Cancer Cell 19, 254-64.
 c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell
lung carcinoma. Blasco R B, Francoz S, Santamaría D, Cañamero M, Dubus P, Charron J,
Baccarini M, and Barbacid M. (2011). Cancer Cell 19, 652-663.
 Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting
oncogeneinduced senescence. Guerra C, Collado M, Navas C, Schuhmacher A J, HernándezPorras I, Cañamero M, Rodriguez-Justo M, Serrano M, and Barbacid M. (2011). Cancer Cell 19,
728-739.
 2012
 EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal
adenocarcinoma. Navas C, Hernández-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid
M. (2012). Cancer Cell 22:318-30.
 Tracking evolution of BRCA1-associated breast cancer. Jonkers J (2012). Cancer Discov 2:
486-488.
 The effects of deregulated DNA damage signalling on cancer chemotherapy response and
resistance. Bouwman P, Jonkers J (2012). Nat Rev Cancer 12: 587-598.
 Using genetically engineered mouse models to validate candidate cancer genes and test
new therapeutic approaches. van Miltenburg MH, Jonkers J (2012). Curr Opin Genet Dev 22: 2127.
 What we have learned about pancreatic cancer from mouse models. Pérez-Mancera PA,
Guerra C, Barbacid M, Tuveson DA. (2012). Gastroenterology 142:1079-92.
 Genomic instability in breast and ovarian cancers: translation into clinical predictive
biomarkers. Vollebergh MA, Jonkers J*, Linn SC* (2012). Cell Mol Life Sci Jan 69: 223-245. (*
joint corresponding authors).
 Impact of intertumoural heterogeneity on predicting chemotherapy response of BRCA1deficient mammary tumours. Rottenberg S, Vollebergh MA, de Hoorn B, de Ronde J, Schouten
PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Lodén M, Sol W, van der Burg E,
Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers J, Borst P (2012).
Cancer Res 72: 2350-2361.
 Proteomics of mouse BRCA1-deficient mammary tumours identifies DNA repair proteins
with diagnostic and prognostic value in human breast cancer. Warmoes M, Jaspes JE, Pham
TV, Piersma SR, Oudgenoeg G, Massink MP, Waisfisz Q, Rottenberg S, Jonkers J, Jimenez C
(2012). Mol Cell Proteomics 11: M111.013334.
 2013
 Loss of 53BP1 causes PARP inhibitor resistance in BRCA1-mutated mouse mammary
tumours. Jaspers J, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R,
Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O’Connor MJ, Ganesan S,
Borst P, Jonkers J*, Rottenberg S*. (2013). Cancer Discov 3: 68-81. (* joint corresponding
authors).
 Proteomics of genetically engineered mouse mammary tumours identifies fatty acid
metabolism members as predictive markers for cisplatin resistance. Warmoes M, Jaspers JE,
Xu G, Sampadi BK, Pham TV, Knol JC, Piersma SR, Boven E, Jonkers J, Rottenberg S, Jimenez
CR. (2013). Mol Cell Proteomics [Epub ahead of print].
WP8
 2012
 NormaCurve: A SuperCurve-Based Method That Simultaneously Quantifies and Normalizes
Reverse Phase Protein Array Data. Troncale S, Barbet A, Coulibaly L, Henry E, He B, Barillot E,
Dubois T, Hupe P, de Koning L. (2012). PLoS ONE 7(6): e38686.
 Unresponsiveness to BRAF(V600E) inhibition of colon cancer through feedback activation
of EGFR. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen R
L, Bardelli A, and Bernards R. (2012). Nature 483, 100-103.
WP9
2012
 DELLY: structural variant discovery by integrated paired-end and split-read analysis.
Rausch T, Zichner T, Schlattl A, Stütz AM, Benes V, Korbel JO. (2012) Bioinformatics Sep
15;28(18):i333-i339. doi: 10.1093/bioinformatics/bts378.
 Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements
with TP53 mutations. Rausch T, Jones DT, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J,
Jäger N, Remke M, Shih D, Northcott PA, Pfaff E, Tica J, Wang Q, Massimi L, Witt H, Bender S,
Pleier S, Cin H, Hawkins C, Beck C, von Deimling A, Hans V, Brors B, Eils R, Scheurlen W, Blake
J, Benes V, Kulozik AE, Witt O, Martin D, Zhang C, Porat R, Merino DM, Wasserman J, Jabado N,
Fontebasso A, Bullinger L, Rücker FG, Döhner K, Döhner H, Koster J, Molenaar JJ, Versteeg R,
Kool M, Tabori U, Malkin D, Korshunov A, Taylor MD, Lichter P, Pfister SM, Korbel JO. (2012) Cell
Jan 20;148(1-2):59-71.
 Tools for mapping high-throughput sequencing data. Fonseca NA, Rung J, Brazma A, Marioni
JC. Bioinformatics. 2012 Dec 15;28(24):3169-77.
2013
 ArrayExpress update--trends in database growth and links to data analysis tools. Rustici G,
Kolesnikov N, Brandizi M, Burdett T, Dylag M, Emam I, Farne A, Hastings E, Ison J, Keays M,
Kurbatova N, Malone J, Mani R, Mupo A, Pedro Pereira R, Pilicheva E, Rung J, Sharma A, Tang
YA, Ternent T, Tikhonov A, Welter D, Williams E, Brazma A, Parkinson H, Sarkans U. Nucleic
Acids Res. 2013 Jan;41(Database issue):D987-90.
WP12
 2012
 Critical Appraisal of Translational Research Models for Suitability in Performance
Assessment of Cancer Centres. Rajan A, Sullivan R, Bakker S, van Harten WH. The Oncologist
2012;17:e48–e57